<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23186897</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>05</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1557-9875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurologic clinics</Title>
          <ISOAbbreviation>Neurol Clin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transverse myelitis.</ArticleTitle>
        <Pagination>
          <StartPage>79</StartPage>
          <EndPage>138</EndPage>
          <MedlinePgn>79-138</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ncl.2012.09.008</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0733-8619(12)00069-2</ELocationID>
        <Abstract>
          <AbstractText>Transverse myelitis (TM) includes a pathobiologically heterogeneous syndrome characterized by acute or subacute spinal cord dysfunction resulting in paresis, a sensory level, and autonomic (bladder, bowel, and sexual) impairment below the level of the lesion. Etiologies for TM can be broadly classified as parainfectious, paraneoplastic, drug/toxin-induced, systemic autoimmune disorders, and acquired demyelinating diseases. We discuss the clinical evaluation, workup, and acute and long-term management of patients with TM. Additionally, we briefly discuss various disease entities that may cause TM and their salient distinguishing features, as well as disorders that may mimic TM.</AbstractText>
          <CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Beh</LastName>
            <ForeName>Shin C</ForeName>
            <Initials>SC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Greenberg</LastName>
            <ForeName>Benjamin M</ForeName>
            <Initials>BM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frohman</LastName>
            <ForeName>Teresa</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frohman</LastName>
            <ForeName>Elliot M</ForeName>
            <Initials>EM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016456">Historical Article</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Clin</MedlineTA>
        <NlmUniqueID>8219232</NlmUniqueID>
        <ISSNLinking>0733-8619</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009188" MajorTopicYN="N">Myelitis, Transverse</DescriptorName>
          <QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23186897</ArticleId>
        <ArticleId IdType="pmc">PMC7132741</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ncl.2012.09.008</ArticleId>
        <ArticleId IdType="pii">S0733-8619(12)00069-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Oppenheim H. Zum Capitel der Myelitis. Berl Klin Wchnschr. 1891;28:761.</Citation>
        </Reference>
        <Reference>
          <Citation>Cree B.A., Wingerchuk D.M. Acute transverse myelitis: is the “idiopathic” form vanishing? Neurology. 2005;65:1857–1858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16380606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frohman E.M., Wingerchuk D.M. Clinical practice. Transverse myelitis. N Engl J Med. 2010;363(6):564–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20818891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Seze J., Stojkovic T., Breteau G. Acute myelopathies: clinical, laboratory, and outcome profiles in 79 cases. Brain. 2001;124:1509–1521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11459743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacob A., Weinshenker B.G. An approach to the diagnosis of acute transverse myelitis. Semin Neurol. 2008;28:105–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18256991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep. 2003;3:256–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12691631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Transverse Myelitis Consortium Group  Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59:499–505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12236201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berman M., Feldman S., Alter M. Acute transverse myelitis: incidence and etiologic considerations. Neurology. 1981;31:966–971.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7196523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeffrey D.R., Mandler R.N., Davis L.E. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol. 1993;50:532–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8489410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhat A., Naguwa S., Cheema G. The epidemiology of transverse myelitis. Autoimmun Rev. 2010;9:A395–A399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20035902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debette S., de Seze J., Pruvo J.P. Long-term outcome of acute and subacute myelopathies. J Neurol. 2009;256:980–988.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19252779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen P.B., Wermuth L., Mulder D.W. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand. 1990;81:431–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2375246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott T.F., Frohman E.M., de Seze J. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128–2134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22156988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ditunno J.F., Little J.W., Tessler A. Spinal shock revisited: a four-phase model. Spinal Cord. 2004;42(7):383–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15037862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogelson J., Williams K. Compressive and traumatic myelopathies. Continuum (Minneap Minn) 2008;14(3):110–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Bakheit A.M. Phantom limb sensations after complete thoracic transverse myelitis. J Neurol Neurosurg Psychiatry. 2000;69(2):275–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1737036</ArticleId>
            <ArticleId IdType="pubmed">10960288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kempster P.A., Rollinson R.D. The Lhermitte phenomenon: variant forms and their significance. J Clin Neurosci. 2008;15(4):379–381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18280165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Layzer R.B. Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet. 1978;312(8102):1227–1230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">82736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todd N.V. Priapism in acute spinal cord injury. Spinal Cord. 2011;49(10):1033–1035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21647168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammond E.R., Kerr D.A. Priapism in infantile transverse myelitis. Arch Neurol. 2009;66(7):894–897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19597093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.M., Go M.J., Sung J.J. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility and clinical characteristics. Arch Neurol. 2012;69(8):1026–1031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22473770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tashiro K. Charles Edward Beevor. J Neurol. 2001;248:635–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11518013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brazis P.W., Masdeu J.C., Biller J.  Localization in clinical neurology. 5th edition. Lippincott Williams &amp; Wilkins; Philadelphia: 2007. Spinal cord; pp. 99–123.</Citation>
        </Reference>
        <Reference>
          <Citation>Blumenfeld H.  Neuroanatomy through clinical cases. Sinauer Associates, Inc; Sunderland (MA): 2002. The neurologic exam as a lesson in neuroanatomy; pp. 49–82.</Citation>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Hogancamp W.F., O'Brien P.C. The clinical course of neuromyelitis optica (Devic's syndrome) Neurology. 1999;53(5):1107–1114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10496275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J., Leite M.I., Nairne A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67(8):1016–1017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20697055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bot J.C., Barkhof F., Lycklama à Nijeholt G.J. Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. Eur Radiol. 2000;10(5):753–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10823627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campi A., Pontesilli S., Gerevini S. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology. 2000;42(9):669–675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11071441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott T.F. Nosology of idiopathic transverse myelitis syndromes. Acta Neurol Scand. 2007;115:371–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17511844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott T.F., Kassab S.L., Singh S. Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis. Mult Scler. 2005;11(4):373–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16042216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon V.A., Wingerchuk D.M., Kryzer T.J. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker B.G., Wingerchuk D.M., Vukusic S. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16453327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLean B.N., Luxton R.W., Thompson E.J. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index. A comparison and diagnostic applications. Brain. 1990;113(Pt 5):1269–1289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2245296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodriguez A., Calogne M., Pedroza-Seres M. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114(5):593–599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8619771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frohman E.M., Frohman T.C., Zee D.S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15664543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syme J.A., Kelly J.J. Absent F-waves early in a case of transverse myelitis. Muscle Nerve. 1994;17:462–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8170494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misra U.K., Kalita J. Can electromyography predict the prognosis of transverse myelitis? J Neurol. 1998;245:741–744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9808244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006;354:942–955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16510748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordonnier C., de Seze J., Breteau G. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol. 2003;250(12):1447–1452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14673577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harzheim M., Schlegel U., Urbach H. Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients. J Neurol Sci. 2004;217:217–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14706227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruna J., Martinez-Yelamos S., Martinez-Yelamos A. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006;12(2):169–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16629419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sellner J., Luthi N., Buhler R. Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis. Eur J Neurol. 2008;15(4):398–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18312402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourre B., Zephir H., Ongagna J.C. Long-term follow-up of acute partial transverse myelitis. Arch Neurol. 2012;69(3):357–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22410443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisniku L.K., Brex P.A., Altmann D.R. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808–817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18234696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkhof F., Filippi M., Miller D.H. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(pt 11):2059–2069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9397021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bashir K., Whitaker J.N. Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI. Mult Scler. 2000;6:312–316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11064439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Riordan J.I., Thompson A.J., Kingsley D.P. The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow up. Brain. 1998;121:495–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9549525</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinelli V., Comi G., Rovaris M. Acute myelopathy of unknown etiology: a clinical, neurophysiological and MRI study of short and long-term prognostic factors. J Neurol. 1995;242:497–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8530976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perumal J., Zabad R., Caon C. Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol. 2008;255(1):89–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18080852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu W., Wu J.S., Zhang M.N. Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database. J Neurol Neurosurg Psychiatry. 2010;81:209–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19710049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Lennon V.A., Pittock S.J. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16717206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lennon V.A., de Seze J. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65:78–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18195142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Lennon V.A., Lucchinetti C.F. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S., Jacobi C., de Seze J. Frequency and specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011;17(9):1067–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21543553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitali C., Bombardieri S., Jonsson R. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1754137</ArticleId>
            <ArticleId IdType="pubmed">12006334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govoni M., Padovan M., Rizzo N. CNS involvement in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs. 2001;15:597–607.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11524032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delalande S., de Seze J., Fauchais A.L. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander E.L., Provost T.T., Stevens M.D. Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore) 1982;61:247–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6283302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudero D., Latorre P., Codina M. Central nervous system disease in Sjögren's syndrome. Ann Med Interne (Paris) 1995;146:239–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7653943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.M., Water P., Vincent A. Sjögren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of NMO. Mult Scler. 2009;15:1062–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19692434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konttinen Y.T., Kinnunen E., Von Bonsdorff M. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren's syndrome. Arthritis Rheum. 1987;30:339–344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3566825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Canhao H., Fonseca J.E., Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjögren's syndrome. J Rheumatol. 2000;27:1102–1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10782846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alcântara C., Gomes M.J., Ferreira C. Rituximab therapy in primary Sjögren's syndrome. Ann N Y Acad Sci. 2009;1173:701–705. (Contemporary Challenges in Autoimmunity)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19758218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9324032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>West S.G. Neuropsychiatric lupus. Rheum Dis Clin North Am. 1994;20(1):129–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8153397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein C., Saidha S., Levy M. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol. 2012;259(5):801–816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21932127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacs B., LaVerty T., Brent L. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1753077</ArticleId>
            <ArticleId IdType="pubmed">10666167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulz S.W., Shenin M., Mehta A. Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases. Rheumatol Int. 2012;32(9):2623–2627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21833518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katsiari C.G., Giavri I., Mitsikostas D.D. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol. 2011;18(4):556–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20840379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertsias G.K., Ioannidis J.P., Aringer M. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–2082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20724309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinosa G., Mendizabal A., Minguez S. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum. 2010;39(4):246–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19022478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birnbaum J., Petri M., Thompson R. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378–3387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19877037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Cruz D.P., Mellor-Pita S., Joven B. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol. 2004;31:280–285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14760797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tellez-Zenteno J.F., Remes-Troche J.M., Negrete-Pulido R.O. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus. 2001;10:851–856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11787874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Provenzale J.M., Barboriak D.P., Gaensler R.L. Lupus-related myelitis: serial MR findings. Am J Neuroradiol. 1994;15:1911–1917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7863941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmaggi A., Lamperti E., Eoli M. Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients. Clin Exp Rheumatol. 1994;12:389–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7955602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok C.C., Lau C.S., Chan E.Y.T. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome. J Rheumatol. 1998;25:467–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9517765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deodhar A.A., Hochenedl T., Bennett R.M. Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis. J Rheumatol. 1999;26:446–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9972984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann-Andersen G., Lindgren S. Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE. Clin Rheumatol. 2000;19:156–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10791631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katramados A.M., Rabah R., Adams M.D. Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus. Lupus. 2008;17:332–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodoridou A., Settas L. Demyelination in rheumatic diseases. Postgrad Med J. 2008;84:127–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18372483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L. Controlled clinical trial of IV cyclophosphamide versus IV methylprenisolone in severe neurological manifestations in systemic lupus erythematous. Ann Rheum Dis. 2005;64:620–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1755456</ArticleId>
            <ArticleId IdType="pubmed">15769918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherer Y., Hassin S., Shoenfeld Y. Transverse myelitis in patients with antiphospholipid antibodies—the importance of early diagnosis and treatment. Clin Rheumatol. 2002;21:207–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12111625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harisdangkul V., Doorenbos D., Subramony S.H. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol. 1995;242:326–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7643142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003;7:173–182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12918940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartolucci P., Bréchignac S., Cohen P. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus. 2007;16:817–822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17895305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong D.J., McCarron M.T., Wright G.D. SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20 monoclonal antibody) Rheumatol Int. 2006;26:771–772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16231119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Y., Qian J., Gu Y. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol. 2011;30(7):981–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21340494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X., Gu Y., Wang Y. Prognostic factors of lupus myelopathy. Lupus. 2008;17:323–328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson W.A., Gharavi A.E., Koike T. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42(7):1309–1311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10403256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cervera R., Piette J.C., Font J. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum. 2002;46:1019–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11953980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.H., Lee S.I., Park S.I. Recurrent transverse myelitis in primary antiphospholipid syndrome: case report and literature review. Rheumatol Int. 2004;24:244–246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14593493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues C.E., de Carvalho J.F. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum. 2011;40(4):349–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20701956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tristano A.G. Acute transverse myelitis as part of the catastrophic antiphospholipid syndrome in a systemic lupus erythematosus patient. Neurologia. 2004;19:774–775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15568177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues C.E., Carvalho J.F., Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40(4):350–359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20192975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tourbah A., Clapin A., Gout O. Systemic autoimmune features and multiple sclerosis. A 5-year follow up. Arch Neurol. 1998;55:517–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9561980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussel V., Yi F., Jauberteau O. Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14:259–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10756088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaarg N., Zivadinov R., Ramanathan M. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol. 2007;187:159–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17512610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stosic M., Ambrus J., Garg N. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol. 2010;257(1):63–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19633967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szmyrka-Kaczmarek M., Pokryszko-Dragan A., Pawlik B. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012;21:412–420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22074845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078–1080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1970380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Araji A., Kidd D. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8:192–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19161910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yesilot N., Mutlu M., Gungoer O. Clinical characteristics and course of spinal cord involvement in Behcet's disease. Eur J Neurol. 2007;14:729–737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17594327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ideguchi H., Suda A., Takeno M. Neurological manifestations of Behcet's disease in Japan: a study of 54 patients. J Neurol. 2010;257(6):1012–1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20127350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akman-Demir G., Serdaroglu P., Tasci B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain. 1999;122:2171–2181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10545401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moskau S., Urbach H., Hartmann A. Multifocal myelitis in Behcet's disease. Neurology. 2003;60(3):517.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12578943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kocer N., Islak C., Siva A. CNS involvement in neuro-Behcet syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015–1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7056254</ArticleId>
            <ArticleId IdType="pubmed">10445437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monaco A.L., Corte R.L., Caniatti L. Neurological involvement in North Italian patients with Behcet's disease. Rheumatol Int. 2006;26:1113–1119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16794844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S.H., Yoon P.H., Park S.J. MRI findings in neuro-Behcet's disease. Clinical Radiol. 2001;56:485–494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11428799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukae J., Noda K., Fujishima K. Subacute longitudinal myelitis associated with Behcet's disease. Intern Med. 2010;49:343–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20154443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrissey S.P., Miller D.H., Hermaszewski R. Magnetic resonance imaging of the central nervous system in Behcet's disease. Eur Neurol. 1993;33:287–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8348915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshioka H., Matsubara T., Miyanomae Y. Spinal cord MRI in neuro-Behcet's disease. Neuroradiology. 1996;38:661–662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8912324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mascalchi M., Cosottini M., Cellerini M. MRI of spinal cord involvement in Behcet's disease: case report. Neuroradiology. 1998;40(4):255–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9592799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green A.L., Mitchell P.J. Spinal cord neuro-Behcet's disease detected on magnetic resonance imaging. Australas Radiol. 2000;44(2):201–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10849985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desphande D.M., Krishnan C., Kerr D.A. Transverse myelitis after lumbar steroid injection in a patient with Behcet's disease. Spinal Cord. 2005;43:735–737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16010282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuolo L., Bonzano L., Roccatagliata C. Reversibility of brain lesions in a case of neuro-Behcet's disease studied by MR diffusion. Neurol Sci. 2010;31(2):213–215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20119742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kidd D., Steuer A., Denman A.M. Neurological complications in Behçet's syndrome. Brain. 1999;122:2183–2194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10545402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coban O., Bahar S., Akman-Demir G. Masked assessment of MRI findings: is it possible to differentiate neuro-Behcet's disease from other central nervous system. Neuroradiology. 1999;41:255–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10344509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B., He L., Lai X.H. A case of neuro-Behcet's disease presenting with lumbar spinal cord involvement. Spinal Cord. 2010;48:172–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19786972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piptone N., Olivieri I., Padula A. Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18240181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serkova N.J., Christians U., Benet L.Z. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004;4:97–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15087483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotake S., Higashi K., Yoshikawa K. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586–589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10080218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato Y., Numaga J., Kato S. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol. 2001;29:335–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11720163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kötter I., Günaydin I., Batra M. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482–486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16261281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lower E.E., Broderick J.P., Brott T.G. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157(16):1864–1868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9290546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapelon C., Ziza J.M., Piette J.C. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990;69(5):261–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2205782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern B.J., Krumholz A., Johns C. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3896208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med. 1977;87(3):336–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">197863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saleh S., Saw C., Marzouk K. Sarcoidosis of the spinal cord: literature review and report of eight cases. J Natl Med Assoc. 2006;98:965–976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569364</ArticleId>
            <ArticleId IdType="pubmed">16775923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joseph F.G., Scolding N.J. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80(3):297–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18977817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen-Aubart F., Galanaud D., Grabli D. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010;89(2):133–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20517184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christoforidis G.A., Spickler E.M., Recio M.V. MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol. 1999;20(4):655–669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7056021</ArticleId>
            <ArticleId IdType="pubmed">10319978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhagavati S., Choi J. Intramedullary cervical spinal cord sarcoidosis. Spinal Cord. 2009;47:179–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18542084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terada T., Shigeno K., Hori M. Isolated spinal neurosarcoidosis: an autopsy case. Spinal Cord. 2010;48:776–778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20212499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lidar M., Dori A., Levy Y. Sarcoidosis presenting as “corset-like” myelopathy: a description of six cases and literature review. Clin Rev Allergy Immunol. 2010;38(2–3):270–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19603148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marangoni S., Argentiero V., Tavolato B., Neurosarcoidosis Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006;253(4):488–495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16283095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer T.S., Campellone J.V., Maldonado I. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum. 2005;34:649–661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15692958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar N., Frohman E.M. Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. Arch Neurol. 2004;61(4):586–589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15096410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakushima K., Yabe I., Nakano F. Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients. J Neurol. 2011;258(12):2163–2167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21553080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zajicek J.P., Scolding N.J., Foster O. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10209662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah R., Roberson G.H., Cure J.K. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol. 2009;30:953–961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7051647</ArticleId>
            <ArticleId IdType="pubmed">19193748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sulavik S.B., Spencer R.P., Weed D.A. Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis. J Nucl Med. 1990;31:1909–1914.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2266386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dale J.C., O'Brien J.F. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74(5):535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10319092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Read R.W., Holland G.N., Rao N.A. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of the international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11336942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lubin J.R., Lowenstein J.I., Fredrick A.R. VKH syndrome with focal neurological signs. Am J Ophthalmol. 1981;91(3):332–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7211990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahbour S.S. MRI documented acute myelitis in a patient with Vogt-Koyanagi-Harada syndrome: first report. Clin Neurol Neurosurg. 2009;111(2):200–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18980794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajendram R., Evans M., Khurana R.N. Vogt-Koyanagi-Harada disease presenting as optic neuritis. Int Ophthalmol. 2007;27(2–3):217–220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17437062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tahara T., Sekitani T. Neurotological evaluation of Harada's disease. Acta Otolaryngol Suppl. 1995;519:110–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7610843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyanaga M., Kawaguchi T., Shimuzu K. Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2–3):183–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17476572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller D.H., Weinshenker B.G., Filippi M. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14(9):1157–1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2850590</ArticleId>
            <ArticleId IdType="pubmed">18805839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tenenbaum S., Chitnis T., Ness J. Acute disseminated encephalomyelitis. Neurology. 2007;68(16 Suppl 2):S32–S36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straussberg R., Schonfeld T., Weitz R. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol. 2001;24:139–143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11275464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aimoto Y., Moriwaka F., Matsumoto K. A case of acute disseminated encephalomyelitis (ADEM) associated with demyelinating peripheral neuropathy. No To Shinkei. 1996;48:857–860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8888036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torisu H., Kira R., Ishizaki Y. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev. 2010;32(6):454–462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19942388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huynh W., Cordato D.J., Kehdi E. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci. 2008;15(12):1315–1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7125578</ArticleId>
            <ArticleId IdType="pubmed">18976924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callen D.J., Shroff M.M., Branson H.M. Role of MRI in the differentiation of ADEM from MS in children. Neurology. 2009;72(11):968–973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19038851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kesselring J., Miller D.H., Robb S.A. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain. 1990;113:291–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2328406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura S., Nezu A., Ohtsuki N. Serial magnetic resonance imaging in children with postinfectious encephalitis. Brain Dev. 1996;18:461–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8980844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franciotta D., Columba-Cabezas S., Andreoni L. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol. 2008;200(1–2):125–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18606457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuve O., Nessler S., Hartung H.P. Acute disseminated encephalomyelitis: pathogenesis, diagnosis, treatment, and prognosis. Nervenarzt. 2005;76(6):701–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15580467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straub J., Chofflon M., Delavelle J. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery. Neurology. 1997;49(4):1145–1147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9339706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stricker R.B., Miller R.G., Kiprov D.D. Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis. J Clin Apher. 1992;7(4):173–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1299654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker B.G., O'Brien P.C., Petterson T.M. A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease. Ann Neurol. 1999;46:878–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10589540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llufriu S., Castillo J., Blanco Y. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology. 2009;73(12):949–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19770470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keegan M., Pineda A.A., McClelland R.L. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58:143–146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11781423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stübgen J.P. Immune-mediated myelitis associated with hepatitis virus infections. J Neuroimmunol. 2011;239(1–2):21–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21945641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi-Fujigasaki J., Takagi S., Sakamoto T. Spinal cord biopsy findings of anti-aquaporin-4 antibody-negative recurrent longitudinal myelitis in a patient with sicca symptoms and hepatitis C viral infection. Neuropathology. 2009;29(4):472–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18992010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aktipi K.M., Ravaglia S., Ceroni M. Severe recurrent myelitis in patients with hepatitis C virus infection. Neurology. 2007;68:468–469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17283325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacheco V.H., Acharya J.N. Recurrent myelopathy and hepatitis C infection. Ann Neurol. 2006;60(Suppl 3):S45.</Citation>
        </Reference>
        <Reference>
          <Citation>Grewal A.K., Lopes M.B., Berg C.L. Recurrent demyelinating myelitis associated with hepatitis C viral infection. J Neurol Sci. 2004;224:101–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15450779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sobukawa E., Sakimura K., Hoshino S. Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Intern Med. 1994;33:718–722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7849390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mandal K., Chopra N. Acute transverse myelitis following hepatitis E virus infection. Indian Pediatr. 2006;43:365–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16651680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seet R.C., Lim E.C., Wilder-Smith E.P. Acute transverse myelitis following dengue virus infection. J Clin Virol. 2006;35(3):310–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16226055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kusuhara T., Nakajima M., Inoue H. Parainfectious encephalomyeloradiculitis associated with herpes simplex virus 1 DNA in cerebrospinal fluid. Clin Infect DIs. 2002;34(9):1199–1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11941546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larik A., Chiong Y., Lee L.C. Longitudinally extensive transverse myelitis associated with dengue fever. BMJ Case Rep. 2012 pii: bcr1220115378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3369397</ArticleId>
            <ArticleId IdType="pubmed">22605876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanthamat N., Sathirapanya P. Acute transverse myelitis associated with dengue viral infection. J Spinal Cord Med. 2010;33(4):425–427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2964032</ArticleId>
            <ArticleId IdType="pubmed">21061903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kincaid O., Lipton H.L. Viral myelitis: an update. Curr Neurol Neurosci Rep. 2006;6(6):469–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17074281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roos K.L. West Nile encephalitis and myelitis. Curr Opin Neurol. 2004;17:343–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15167070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solomon T., Dung N.M., Kneen R. Japanese encephalitis. J Neurol Neurosurg Psychiatry. 2000;68:405–415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736874</ArticleId>
            <ArticleId IdType="pubmed">10727474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Einsiedel L., Kat E., Ravindran J. MR findings in Murray Valley encephalitis. AJNR Am J Neuroradiol. 2003;24:1379–1382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12917132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bender A. Severe tick borne encephalitis with simultaneous brain stem, bithalamic, and spinal cord involvement documented by MRI. J Neurol Neurosurg Psychiatry. 2005;76:135–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739305</ArticleId>
            <ArticleId IdType="pubmed">15608016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheibe F., Hofmann J., Ruprecht K. Parainfectious myelitis associated with parvovirus B19 infection. J Neurol. 2010;257:1557–1558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20339862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton L.L., Hyndman N.J. Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. Pediatrics. 2000;105:e35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10699137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arpino C., Curatolo P., Rezza G. Chikungunya and the nervous system: what we do and do not know. Rev Med Virol. 2009;19(3):121–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19274635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huisa B.N., Chapin J.E., Adair J.C. Central nervous system complications following Hanta virus cardiopulmonary syndrome. J Neurovirol. 2009;15(2):202–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19089788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Unay B., Kendirli T., Meral C. Transverse myelitis due to echovirus type 30. Acta Paediatr. 2005;94(12):1863–1864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16421057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponka A. Central nervous system manifestations associated with serologically verified Mycoplasma pneumoniae infection. Scand J Infect Dis. 1980;12:175–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7433917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassell G.H., Cole B.C. Mycoplasmas as agents of human disease. N Engl J Med. 1981;304:80–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6777700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review. Clin Infect Dis. 1993;17(Suppl 1):S52–S57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7110383</ArticleId>
            <ArticleId IdType="pubmed">8399938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsiodras S., Kelesidis T.H., Kelesidis I. Mycoplasma pneumoniae-associated myelitis: a comprehensive review. Eur J Neurol. 2006;13:112–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16490040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isoda H., Ramsey R. MR imaging of acute transverse myelitis (myelopathy) Radiat Med. 1998;16:179–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9715996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goebels N., Helmchen C., Abele-Horn M. Extensive myelitis associated with Mycoplasma pneumoniae infection: magnetic resonance imaging and clinical long-term follow-up. J Neurol. 2001;248:204–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11355154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csabi G., Komaromy H., Hollody K. Transverse myelitis as a rare, serious complication of Mycoplasma pneumoniae infection. Pediatr Neurol. 2009;41(4):312–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19748056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gozzard P., Orr D., Sanderson F. Acute transverse myelitis as a rare manifestation of Campylobacter diarrhoea with concomitant disruption of the blood brain barrier. J Clin Neurosci. 2012;19:316–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22133816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baar I., Jacobs B.C., Govers N. Campylobacter jejuni-induced acute transverse myelitis. Spinal Cord. 2007;45:690–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17297497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aberle J., Kluwe J., Pawlas F. Severe myelitis following infection with Campylobacter enteritis. Eur J Clin Microbiol Infect Dis. 2004;23:134–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14727151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber S., Kappos L., Fuhr P. Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni. J Neurol. 1999;246:1204–1206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10653319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orr D., McKendrick M.W., Sharrack B. Acute disseminated encephalomyelitis temporally associated with Campylobacter gastroenteritis. J Neurol Neurosurg Psychiatry. 2004;75:792–793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1763574</ArticleId>
            <ArticleId IdType="pubmed">15090589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaig C., Valldeoriola F., Saiz A. Acute disseminated encephalomyelitis associated with Campylobacter jejuni infection and antiganglioside GM1 IgG antibodies. J Neurol. 2005;252:613–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15778812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasralla C.A., Pay N., Goodpasture H.C. Postinfectious encephalopathy in a child following Campylobacter jejuni enteritis. AJNR Am J Neuroradiol. 1993;14:444–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8456726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bigi S., Aebi C., Nauer C. Acute transverse myelitis in Lyme neuroborreliosis. Infection. 2010;38(5):413–416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20505978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pourhassan A., Shoja M.M., Tubbs R.S. Acute transverse myelitis secondary to Salmonella paratyphi B infection. Infection. 2008;36(2):170–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17906841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ubogu E.E., Lindenberg J.R., Werz M.A. Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection. Reg Anesth Pain Med. 2003;28(5):470–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14556140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waltereit R., Küker W., Jürgens S. Acute transverse myelitis associated with Coxiella burnetii infection. J Neurol. 2001;249(10):1459–1461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12532936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schimmel M.S., Schlesinger Y., Berger I. Transverse myelitis: unusual sequelae of neonatal group B streptococcus disease. J Perinatol. 2002;22(7):580–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12368977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pickerill R.G., Milder J.E. Transverse myelitis associated with cat-scratch disease in an adult. JAMA. 1981;246:2840–2841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7310976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salgado C.D., Weisse M.E. Transverse myelitis associated with probable cat-scratch disease in a previously healthy pediatric patient. Clin Infect Dis. 2000;31(2):609–611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10987731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams W., Sunderland R. As sick as a pigeon; psittacosis myelitis. Arch Dis Child. 1989;64:1626–1628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1792635</ArticleId>
            <ArticleId IdType="pubmed">2604425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crook T., Bannister B. Acute transverse myelitis associated with Chlamydia psittaci infection. J Infect. 1996;32(2):151–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8708374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Lau L.M., Siepman D.A., Remmers M.J. Acute disseminating encephalomyelitis following Legionnaires disease. Arch Neurol. 2010;67(5):623–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20457963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K.L., Lee J.K., Yim Y.M. Acute transverse myelitis associated with scrub typhus: case report and a review of literature. Diagn Microbiol Infect Dis. 2008;60(2):237–239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17997258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Y., Guo N., Liu J. Mycobacteria infection in incomplete transverse myelitis is refractory steroids: a pilot study. Clin Dev Immunol. 2011;2011:501369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3038615</ArticleId>
            <ArticleId IdType="pubmed">21331384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan C., Kaplin A.I., Graber J.S. Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression. J Neurovirol. 2005;11:225–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16036801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baylor P., Garoufi A., Karpathios T. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease) Clin Infect Dis. 2007;45:e42–e45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17638185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gumbo T., Hakim J.G., Mielke J. Cryptococcus myelitis: atypical presentation of a common infection. Clin Infect Dis. 2001;32:1235–1236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11283816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shields G.S., Castillo M. Myelitis caused by Cladophialophora bantiana. AJR Am J Roentgenol. 2002;179:278–279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12076955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jabbour R.A., Kanj S.S., Sawaya R.A. Toxocara canis myelitis: clinical features, magnetic resonance imaging (MRI) findings, and treatment outcome in 17 patients. Medicine (Baltimore) 2011;90(5):337–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21862933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dauriac-Le Masson V., Chochon F., Demeret S. Toxocara canis meningomyelitis. J Neurol. 2005;252(10):1267–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16200465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marx C., Lin J., Masruha M.R. Toxocariasis of the CNS simulating acute disseminated encephalomyelitis. Neurology. 2007;69(8):806–807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17709716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helsen G., Vandecasteele S.J., Vanopdenbosch L.J. Toxocariasis presenting as encephalomyelitis. Case Report Med. 2011;2011:503913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3099216</ArticleId>
            <ArticleId IdType="pubmed">21629809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross A.G., McManus D.P., Farrar J. Neuroschistosomiasis. J Neurol. 2012;259:22–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21674195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunyaratavej K., Pongpunlert W., Jongwutiwes S. Spinal gnathostomiasis resembling an intrinsic cord tumor/myelitis in a 4-year-old boy. Southeast Asian J Trop Med Public Health. 2008;39:800–803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19058570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kibiki G.S., Murphy D.K. Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man. J Neurol Neurosurg Psychiatry. 2006;77:684–685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2117437</ArticleId>
            <ArticleId IdType="pubmed">16614036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drulovic J., Dujmovic I., Stojsavljevic N. Transverse myelopathy in the antiphospholipid antibody syndrome: pinworm infestation as a trigger? J Neurol Neurosurg Psychiatry. 2000;68:246–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736799</ArticleId>
            <ArticleId IdType="pubmed">10702040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesca G., Deschamps R., Lubetzki C. Acute myelitis in early Borrelia burgdorferi infection. J Neurol. 2002;249:1472–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12532941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumann M., Birnbacher R., Koch J. Uncommon manifestations of neuroborreliosis in children. Eur J Paediatr Neurol. 2010;14:274–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19748808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajaj N.P.S., Rose P., Clifford-Jones R. Acute transverse myelitis and Guillain-Barre overlap syndrome with serological evidence for mumps viraemia. Acta Neurol Scand. 2001;104:239–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11589654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venketasubramanian N. Transverse myelitis following mumps in an adult—a case report with MRI correlation. Acta Neurol Scand. 1997;96:328–331.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9405004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigamonti A., Usai S., Ciusani E. Atypical transverse myelitis due to cytomegalovirus in an immunocompetent patient. Neurol Sci. 2005;26:351–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16388372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ku B., Lee K. Acute transverse myelitis caused by Coxsackie virus B4 infection: a case report. J Korean Med Sci. 1998;13:449–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3054412</ArticleId>
            <ArticleId IdType="pubmed">9741555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minami K., Tsuda Y., Maeda H. Acute transverse myelitis caused by Coxsackie virus B5 infection. J Paediatr Child Health. 2004;40:66–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14718010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chortis P. Study in the therapy of transverse myelitis occurring during tuberculous meningitis. Dis Chest. 1958;33:506–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13524095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMinn P., Stratov I., Nagarajan L. Neurological manifestations of Enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001;32(2):236–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11170913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruhn B., Meerbach A., Egerer R. Successful treatment of Epstein-Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation. Bone Marrow Transplant. 1999;24:1355–1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10627648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caldas C., Bernicker E., Dal Nogare A. Case report: transverse myelitis associated with Epstein-Barr virus infection. Am J Med Sci. 1994;307:45–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8291507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corssmit E.P., Leverstein-van Hall M., Portegies P. Severe neurological complications in association with Epstein-Barr virus infection. J Neurovirol. 1997;3:460–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9475119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umehara F., Ookatsu H., Hayashi D. MRI studies of spinal visceral larva migrans syndrome. J Neurol Sci. 2006;249:7–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16815465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee I.H., Kim S.T., Oh D.K. MRI findings of spinal visceral larva migrans of Toxocara canis. Eur J Radiol. 2010;75:236–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19447576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joshi T.N., Yamazaki M.K., Zhao H. Spinal schistosomiasis: differential diagnosis for acute paraparesis in a U.S. resident. J Spinal Cord Med. 2010;33(3):256–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920119</ArticleId>
            <ArticleId IdType="pubmed">20737799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hull T.P., Bates J.H. Optic neuritis after influenza vaccination. Am J Ophthalmol. 1997;124:703–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9372734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray C.L., Dreizin I.J. Bilateral optic neuropathy associated with influenza vaccination. J Neuroophthalmol. 1996;16:182–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8865010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keegan B.M., Pittock S.J., Lennon V.A. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol. 2008;63(4):531–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18306241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross S.A., Salomao D.R., Parisi J.E. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5 IgG. Ann Neurol. 2003;54:38–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12838519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Yoshikawa H., Ahlskog J.E. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81:1207–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16970217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka M., Matsushita T., Tateishi T. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology. 2008;71(13):974–981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18809833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoli A., Mariano M., Fusari A. Atopic myelitis: first case report outside Japan? Allergy. 2005;60:410–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15679734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregoire S.M., Mormont E., Laloux P. Atopic myelitis: a clinical, biological, radiological and histopathological diagnosis. J Neurol Sci. 2006;247:231–235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16782129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kira J., Kawano Y., Horiuchi I. Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis) J Neurol Sci. 1999;162(1):56–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10064169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kira J., Yamasaki K., Kawano Y. Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci. 1997;148(2):199–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9129117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isobe N., Kanamori Y., Yonekawa T. First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci. 2012;316:30–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22364869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Constantinescu C.S., Thomas M., Zaman A.G. Atopic optic neuritis. Ocul Immunol Inflamm. 2006;14:125–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16597543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Seze J., Lanctin C., Lebrun C. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005;65(12):1950–1953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16380618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan C., Kaplin A., Deshpande D. Transverse myelitis: pathogenesis, diagnosis and treatment. Front Biosci. 2004;9:1483–1499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14977560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvarenga M.P., Thuler L.C., Neto S.P. The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol. 2010;257(6):992–998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20127351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi K.H., Lee K.S., Chung S.O. Idiopathic transverse myelitis: MR characteristics. AJNR Am J Neuroradiol. 1996;17:1151–1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8791931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alper G., Petropoulou K.A., Fitz C.R. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17:74–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022414</ArticleId>
            <ArticleId IdType="pubmed">20858691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young J., Quinn S., Hurrell M. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler. 2009;15(11):1295–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19812117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S.H., Kim S.M., Vincent A. Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol. 2010;257(6):920–925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20049472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravaglia S., Bastianello S., Franciotta D. NMO-IgG-negative relapsing myelitis. Spinal Cord. 2009;47:531–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19104509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim K.K. Idiopathic recurrent transverse myelitis. Arch Neurol. 2003;60:1290–1294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12975297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pidcock F.S., Krishnan C., Crawford T.O. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68:1474–1480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17470749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas T., Branson H.M., Leonard H. The demographic, clinical and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol. 2012;27:11–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21968984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andronikou S., Albuquerque-Jonathan G., Wilmshurst J. MRI findings in acute idiopathic transverse myelopathy in children. Pediatr Radiol. 2003;33:624–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12879317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defresne P., Hollenberg H., Husson B. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 2003;18:401–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12886975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knebusch M., Strassburg H.M., Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol. 1998;40:631–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9766742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunne K., Hopkins I.J., Shield L.K. Acute transverse myelopathy in childhood. Dev Med Child Neurol. 1986;28:198–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3709989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiu E.M., Kornberg A.J., Ryan M.M. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities? J Child Neurol. 2009;24:287–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19258287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Goede C.G., Holmes E.M., Pike M.G. Acquired transverse myelopathy in children in the United Kingdom—a 2 year prospective study. Eur J Paediatr Neurol. 2010;14:479–487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20089428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Banwell B., Tenembaum S., Lennon V.A. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology. 2008;70:344–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18094334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang K.C., Wang S.J., Lee C.L. The rescue effect of plasma exchange for neuromyelitis optica. J Clin Neurosci. 2011;18:43–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwathmey K., Balogun R.A., Burns T. Neurologic indications for therapeutic plasma exchange: an update. J Clin Apher. 2011;26(5):261–268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21915895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg B.M., Thomas K.P., Krishnan C. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–1617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17485649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan O.A., Zvartau-Hind M., Caon C. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler. 2001;7:185–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11475443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci. 2004;223:73–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15261565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borchers A.T., Gershwin M.E. Transverse myelitis. Autoimmun Rev. 2012;11:231–248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21621005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson A.J. Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Curr Opin Neurol. 2005;18:267–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15891410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trecker C.C., Kozubal D.E., Quigg M. Quality care in transverse myelitis: a responsive protocol. J Child Neurol. 2009;24:577–583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19211922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yavin Y., Cohan A.T. Venous thromboembolism prophylaxis for the medical patient: where do we stand? Semin Respir Crit Care Med. 2008;29(1):75–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18302089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anders J., Heinemann A., Carsten L. Decubitus ulcers: pathophysiology and primary prevention. Dtsch Arztebl Int. 2010;107(21):371–382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2883282</ArticleId>
            <ArticleId IdType="pubmed">20539816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Putzke J., Richards J., Hicken B. Predictors of life satisfaction: a spinal cord injury cohort study. Arch Phys Med Rehabil. 2002;83:555–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11932861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ditunno P.L., Patrick M., Stineman M. Who wants to walk? Preferences for recovery after SCI: a longitudinal and cross-sectional study. Spinal Cord. 2008;46:500–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18209742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietz V. Neurophysiology of gait disorders: present and future applications. Electroencephalogr Clin Neurophysiol. 1997;103(3):333–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9305281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scivoletto G., Romanelli A., Mariotti A. Clinical factors that affect walking level and performance in chronic spinal cord lesion patients. Spine (Phila Pa 1976) 2008;33(3):259–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18303457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lapointe R., Lajoie Y., Serresse O. Functional community ambulation requirements in incomplete spinal cord injured subjects. Spinal Cord. 2001;39:327–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11438855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sturt R.N., Holland A.E., New P.W. Walking ability at discharge from inpatient rehabilitation in a cohort of non-traumatic spinal cord injury patients. Spinal Cord. 2009;47(10):763–768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19365395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courtney A.M., Castro-Borrero W., Davis S.L. Functional treatments in multiple sclerosis. Curr Opin Neurol. 2011;24(3):250–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21455067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golzari Z., Shabkhiz F., Soudi S. Combined exercise training reduces IFN-g and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010;10:1415–1419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20797460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawker K., Frohman E., Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol. 2003;60:1772–1774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14676055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rittweger J., Gerrits K., Altenburg T. Bone adaptation to altered loading after spinal cord injury: a study of bone and muscle strength. J Musculoskelet Neuronal Interact. 2006;6:269–276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17142949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roze E., Bounolleau P., Ducreux D. Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings. Neurology. 2009;72(15):1301–1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19365051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown L.K., Heffner J.E., Obbens E.A. Tranverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen. Sleep. 2000;23(5):1–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10947026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Natarajan R. Review of periodic limb movement and restless leg syndrome. J Postgrad Med. 2010;56(2):157–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20622400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalita J., Shah S., Kapoor R. Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations. J Neurol Neurosurg Psychiatry. 2002;73(2):154–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1737981</ArticleId>
            <ArticleId IdType="pubmed">12122174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta A., Taly A.B., Srivastava A. Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord. 2009;47:307–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18936767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka S.T., Stone A.T., Kurzrock E.A. Transverse myelitis in children: long-term urological outcomes. J Urol. 2006;175(5):1864–1868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16600781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemack G.E., Frohman E.M., Zimmern P.E. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. Urology. 2006;67:960–964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16635509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samkoff L.M., Goodman A.D. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29(2):449–463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21439453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fowler C.J., Panicker J.N., Drake M. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J. 2009;85(1008):552–559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19789195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebert E. Gastrointestinal involvement in spinal cord injury: a clinical perspective. J Gastrointestin Liver Dis. 2012;21(1):75–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22457863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raghav S., Kipp D., Watson J. Gastroparesis in multiple sclerosis. Mult Scler. 2006;12(2):243–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16629430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddymasu S.C., Bonino J., McCallum R.W. Gastroparesis secondary to a demyelinating disease: a case series. BMC Gastroenterol. 2007;7:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1800858</ArticleId>
            <ArticleId IdType="pubmed">17266755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atkinson K., Romano W., Prokopiw I. An unusual cause of gastroparesis: demyelinating disease of the medulla. Dig Dis Sci. 1998;43:1430–1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9690376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Read S.J., Leggett B.A., Pender M.P. Gastroparesis with multiple sclerosis. Lancet. 1995;346(8984):1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7475681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiesel P.H., Norton C., Glickman S. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001;13(4):441–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11338078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen P., Krogh K., Buntzen S. Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence. Dis Colon Rectum. 2009;52:286–292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19279425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Consortium for Spinal Cord Medicine  Sexuality and reproductive health in adults with spinal cord injury: a clinical practice guideline for health-care professionals. J Spinal Cord Med. 2010;33(3):281–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2941243</ArticleId>
            <ArticleId IdType="pubmed">20737805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G., Mondaini N., Iazzetta P. Sexuality in patients with spinal cord injuries due to attempted suicide. Spinal Cord. 2008;46(1):53–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17420774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forsythe E., Horsewell J.E. Sexual rehabilitation of women with a spinal cord injury. Spinal Cord. 2006;44:234–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16172622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courtois F.J., Charvier K.F., Leriche A. Sexual function in spinal cord injury men. Assessing sexual capability. Paraplegia. 1993;31:771–784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8115170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Courtois F.J., Goulet M.C., Charvier K.F. Posttraumatic erectile potential of spinal cord injured men: How physiologic recordings supplement subjective reports. Arch Phys Med Rehabil. 1999;80:1268–1272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10527086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander M.S., Biering-Sorensen F., Bodner D. International standards to document remaining autonomic function after spinal cord injury. Spinal Cord. 2009;47:36–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18957962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone A.R. The sexual needs of the injured spinal cord patient. Probl Urol. 1987;1:529–536.</Citation>
        </Reference>
        <Reference>
          <Citation>Barbonetti A., Cavallo F., Felzani G. Erectile dysfunction is the main determinant of psychological distress in men with spinal cord injury. J Sex Med. 2012;9(3):830–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22188659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson K.D., Borisoff J.F., Johnson R.D. Long-term effects of spinal cord injury on sexual function in men: implications for neuroplasticity. Spinal Cord. 2007;45:338–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17016492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G., Del Popolo G., Macchiarella A. Sexual rehabilitation in women with spinal cord injury: a critical review of the literature. Spinal Cord. 2010;48(12):842–849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20386552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G., Mondaini N., Macchiarella A. Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients. J Androl. 2007;28(5):722–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17494102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soler J.M., Previnaire J.G. Ejaculatory dysfunction in spinal cord injury is suggestive of dyssynergic ejaculation. Eur J Phys Rehabil Med. 2011;47:677–681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22222964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreuter M., Taft C., Siösteen A. Women's sexual functioning and sex life after spinal cord injury. Spinal Cord. 2011;49(1):154–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20458327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krassioukov A.V., Karlsson A.K., Wecht A.K. Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment. J Rehabil Res Dev. 2007;44(1):103–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17551864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996;46(5):1470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8628505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidorov E.V., Townson A.F., Dvorak M.F. Orthostatic hypotension in the first month following acute spinal cord injury. Spinal Cord. 2008;46(1):65–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17420772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen E.B., Nordenbo A.M. Sympathetic vasoconstrictor responses in multiple sclerosis with thermo-regulatory dysfunction. Clin Auton Res. 1997;7:13–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9074824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis S.L., Wilson T.E., White A.T. Thermoregulation in multiple sclerosis. J Appl Physiol. 2010;109(5):1531–1537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2980380</ArticleId>
            <ArticleId IdType="pubmed">20671034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krassioukov A.V., Furlan J.C., Fehlings M.G. Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity. J Neurotrauma. 2003;20(8):707–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12965050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krassioukov A., Warburton D.E., Teasell R. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009;90(4):682–695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3108991</ArticleId>
            <ArticleId IdType="pubmed">19345787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braddom R.L., Rocco J.F. Autonomic dysreflexia. Am J Phys Med Rehabil. 1991;70:234–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1910647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho C.P., Krassioukov A.V. Autonomic dysreflexia and myocardial ischemia. Spinal Cord. 2010;48(9):714–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20125109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaves C.J., Lee G. Reversible posterior leukoencephalopathy in a patient with autonomic dysreflexia: a case report. Spinal Cord. 2008;46(11):760–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18427565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dolinak D., Balraj E. Autonomic dysreflexia and sudden death in people with traumatic spinal cord injury. Am J Forensic Med Pathol. 2007;28(2):95–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17525555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beard J.P., Wade W.H., Barber D.B. Sacral insufficiency stress fracture as etiology of positional autonomic dysreflexia: case report. Paraplegia. 1996;34(3):173–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8668359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claydon V.E., Elliott S.L., Sheel A.W. Cardiovascular responses to vibrostimulation for sperm retrieval in men with spinal cord injury. J Spinal Cord Med. 2006;29(3):207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1864810</ArticleId>
            <ArticleId IdType="pubmed">16859224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szasz G., Carpenter C. Clinical observations in vibratory stimulation of the penis of men with spinal cord injury. Arch Sex Behav. 1989;18(6):461–474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2604539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. CMAJ. 2003;169(9):931–935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC219629</ArticleId>
            <ArticleId IdType="pubmed">14581313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sjölund B.H. Pain and rehabilitation after spinal cord injury: the case of sensory spasticity? Brain Res Brain Res Rev. 2002;40:250–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12589923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollmann W., Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18336059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bond L.D., Jr., Keough G.C. Neurogenic pruritus: a case of pruritus induced by transverse myelitis. Br J Dermatol. 2003;149(1):204–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12890224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biering-Sorensen F., Bohr H., Schaadt O. Bone mineral content of the lumbar spine and lower extremities years after spinal cord lesion. Paraplegia. 1988;26:293–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3205570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts D., Lee W., Cuneo R.C. Longitudinal study of bone turnover after acute spinal cord injury. J Clin Endocrinol Metab. 1998;83:415–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9467550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maïmoun L., Fattal C., Micallef J.P. Bone loss in spinal cord-injured patients: from physiopathology to therapy. Spinal Cord. 2006;44(4):203–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16158075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dionyssiotis Y. Spinal cord injury-related bone impairment and fractures: an update on epidemiology and physiopathological mechanisms. J Musculoskelet Neuronal Interact. 2011;11(3):257–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21885901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naftchi N.E., Viau A.T., Sell G.H. Mineral metabolism in spinal cord injury. Arch Phys Med Rehabil. 1980;61:139–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7369852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oleson C.V., Patel P.H., Wuermser L.A. Influence of season, ethnicity, and chronicity on vitamin D deficiency in traumatic spinal cord injury. J Spinal Cord Med. 2010;33(3):202–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920113</ArticleId>
            <ArticleId IdType="pubmed">20737793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pepe J., Romagnoli E., Nofroni I. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int. 2005;16(7):805–812.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15551058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiremath G.S., Cettomai D., Baynes M. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler. 2009;15(6):735–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19383644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599–612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20494325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munger K.L., Levin L.I., Hollis B.W. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17179460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birmingham D.J., Hebert L.A., Song H. Evidence that abnormally large seasonally declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012;21(8):855–864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3839052</ArticleId>
            <ArticleId IdType="pubmed">22433915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braun-Moscovici Y., Toledano K., Markovits D. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatol Int. 2011;31(4):493–499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20033415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy M.A., Newsome S., Greenberg B.M. Low vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol. 2012;69(3):352–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22083799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gannage-Yared M.H., Azoury M., Mansour I. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest. 2003;26(8):748–753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14669830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickie L.J., Church L.D., Coulthard L.R. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) 2010;49(8):1466–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20435648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Correale J., Ysrraelit M.C., Gaitán M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(5):1146–1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19321461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang J., Zhou R., Luger D. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol. 2009;182(8):4624–4632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756755</ArticleId>
            <ArticleId IdType="pubmed">19342637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prietl B., Pilz S., Wolf M. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases? Isr Med Assoc J. 2010;12(3):136–139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20684175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holick M.F. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Current Opin Endocrinol Diabetes. 2002;9(1):87–98.</Citation>
        </Reference>
        <Reference>
          <Citation>Hahn T.J., Hendin B.A., Scharp C.R. Effect of chronic anticonvulsant therapy on serum 25-hydroxycholecalciferol levels in adults. N Engl J Med. 1972;287(18):900–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4561667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vieth R. Critique of the considerations for establishing the tolerable upper intake for vitamin D: critical need for revision upwards. J Nutr. 2006;136:1117–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16549491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldberg P., Flemin M.C., Picard E.H. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21:193–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3537648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heaney R.P., Davies K.M., Chen T.C. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12499343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trang H.M., Cole D.E., Rubin L.A. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68(4):854–858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9771862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giovannucci E., Liu Y., Rimm E.B. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16595781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robsahm T.E., Tretli S., Dahlback A. Vitamin D3 from sunlight may improve the prognosis of breast, colon, and prostate cancer (Norway) Cancer Causes Control. 2004;15(2):149–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15017127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mowe M., Haug E., Bohmer T. Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc. 1999;47(2):220–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9988294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeifer M., Begerow B., Minne H.W. Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes. 2001;109(2):87–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11341304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plotkinoff G.A., Quigley B.A. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78(12):1463–1470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14661675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patten S.B., Beck C.A., Williams J.V. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–1527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14663036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohr D.C., Goodkin D.E., Likosky W. Treatment of depression improves adherence to interferon B-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9152109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edgar M.A. Nervous system involvement in ankylosing spondylitis. BMJ. 1974;1:394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1633620</ArticleId>
            <ArticleId IdType="pubmed">4819194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh D.H., Jun J.B., Kim H.T. Transverse myelitis in a patient with longstanding ankylosing spondylitis. Clin Exp Rheumatol. 2001;19:195–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11326484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan H.H., Chen D.Y., Chen C.C. Combination of transverse myelitis and arachnoiditis in cauda equina syndrome of long-standing ankylosing spondylitis: MRI features and its role in clinical management. Clin Rheumatol. 2007;26:1963–1967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17332972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rath J.J.G., Ronday H.K., Wirtz P.W. Acute transverse myelitis in psoriatic arthritis. J Neurol. 2010;257:457–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20012314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss T.D., Nelson J.S., Woolsey R.M. Transverse myelitis in mixed connective tissue disease. Arthritis Rheum. 1978;21(8):982–986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">737023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pedersen C., Bonen H., Boesen F. Transverse myelitis in mixed connective tissue disease. Case report. Clin Rheumatol. 1987;6:290–292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3621848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flechtner K.M., Baum K. Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. J Neurol Sci. 1994;126:146–148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7853019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok C.C., Lau C.S. Transverse myelopathy complicating mixed connective tissue disease. Case report. Clin Neurol Neurosurg. 1995;97:259–260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7586861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weatherby S.J.M., Davies M.B., Hawkins C.P. Transverse myelopathy, a rare complication of mixed connective tissue disease: comparison with SLE related transverse myelopathy. J Neurol Neurosurg Psychiatry. 2000;68:532–541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1736888</ArticleId>
            <ArticleId IdType="pubmed">10847794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhinder S., Harbour K., Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease—a case report and a review of literature. Clin Rheumatol. 2007;26:445–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16391892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torabi A.M., Patel R.K., Wolfe G.I. Transverse myelitis in systemic sclerosis. Arch Neurol. 2004;61:126–128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14732630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franciotta D., Zardini E., Caporali R. Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. J Neurol Sci. 2011;303:139–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21296362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J.J., Murphy M.J. Transverse myelopathy in progressive systemic sclerosis. Ann Neurol. 1985;17:615–617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4026234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Averbuch-Heller L., Steiner I., Abramski O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol. 1992;49:1292–1295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1333182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray D.W., Bridger J., Hawnaur J. Transverse myelitis as the presentation of Jo-1 antibody syndrome (myositis and fibrosing alveolitis) in long-standing ulcerative colitis. Br J Rheumatol. 1993;32:1105–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8252324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bolla G., Disdier P., Verrot D. Acute transverse myelitis and primary urticarial vasculitis. Clin Rheumatol. 1998;17:250–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9694064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakashima I., Fujihara K., Endo M. Clinical and laboratory features of myelitis patients with anti-neutrophil cytoplasmic antibodies. J Neurol Sci. 1998;157(1):60–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9600678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton A.J., Whitehead D.J., Bull M.D. Systemic pANCA-associated vasculitis with central nervous involvement causing recurrent myelitis: case report. BMC Neurol. 2010;10:118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3001708</ArticleId>
            <ArticleId IdType="pubmed">21118568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bürk K., Farecki M.L., Lamprecht G. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord. 2009;24:2358–2362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19845007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammond E.R., Pardo C.A., Kerr D.A. Thymic hyperplasia in a patient with recurrent transverse myelitis with clinical resolution after thymectomy. J Neurol Neurosurg Psychiatry. 2008;79:334–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18281453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drobyski W.R., Potluri J., Sauer D. Autoimmune hemolytic anemia following T-cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17:1093–1099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8807120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richard S., Fruchtman S., Scigliano E. An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia. Bone Marrow Transplant. 2000;26:1225–1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11149736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Montes R., Richard C., Baro J. Acute transverse myelitis and autoimmune pancytopenia after unrelated hematopoietic cell transplantation. Haematologica. 2001;86(5):556–557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11410429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar N., Hagan J.B., Abraham R.S. Common variable immunodeficiency-associated myelitis: report of treatment with infliximab. J Neurol. 2008;255(11):1821–1824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18677641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermaszewski R.A., Webster A.D. Primary hypogammaglobulinemia: a survey of clinical manifestations and complications. Q J Med. 1993;86:31–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8438047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leypoldt F., Eichhorn P., Saager C. Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis. J Neurol Neurosurg Psychiatry. 2006;77(10):1199–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2077551</ArticleId>
            <ArticleId IdType="pubmed">16980662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Lennon V.A. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53(5):580–587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock S.J., Lucchinetti C.F., Parisi J.E. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15984030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamard L., Magnin E., Berger E. Stiff leg syndrome and myelitis with anti-amphiphysin antibodies: a common physiopathology? Eur Neurol. 2011;66:253–255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21986240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saiz A., Blanco Y., Sabater L. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–2563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18687732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitaliani R., Mason W., Ances B. Paraneoplastic encephalitis, psychiatric symptoms and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58:594–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2245881</ArticleId>
            <ArticleId IdType="pubmed">16178029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruer M.C., Koch T.K., Bourdette D.N. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology. 2010;74:1473–1475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2872802</ArticleId>
            <ArticleId IdType="pubmed">20439851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennington C., Livingstone S., Santosh C. N-Methyl-D-aspartate receptor antibody encephalitis associated with myelitis. J Neurol Sci. 2012;317:151–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22459355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cay H.F., Gungor H.A., Sezer I. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther. 2006;31(6):645–648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17176371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saieg N.A., Luzar M.J. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33:1202–1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16755671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oleginski T.P., Harrington T.M., Carlson J.P. Transverse myelitis secondary to sulfasalazine. J Rheumatol. 1991;18(2):304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1673725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M., Li B., Li J. Acute transverse myelopathy probably related to intravenous gemcitabine plus cisplatin. Ann Pharmacother. 2011;45(4):544–545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21487077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M.Y., Arnold A.C., Vinters H.V. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol. 2000;130:367–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11020424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker W.J., Royer G.L., Jr., Weiss R.B. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1648599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Resar L., Phillips P., Kastan M. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993;71:117–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8416707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crawford S., Rustin G., Bagshawe K. Acute neurological toxicity of intrathecal cytosine arabinoside: a case report. Cancer Chemother Pharmacol. 1986;16:306–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3698171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinsdale T. Spinal analgesia and cauda equina lesions. Anaesthesia. 1947;2:17–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20266325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dawkins C.J. An analysis of the complications of extradural and caudal block. Anaesthesia. 1969;24:554–563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4242599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newberry J.M. Paraplegia following general anaesthesia. Anaesthesia. 1977;32:78–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">848708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schreiner E.J., Lipson S.F., Bromage P.R. Neurological complications following general anaesthesia. Three cases of major paralysis. Anaesthesia. 1983;38:226–229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6301308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitching A., Taylor S. A postoperative neurological problem. Anaesthesia. 1989;44:695–696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2782580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutowsky N.J., Davies A.O. Transverse myelitis following general anaesthesia. Anaesthesia. 1993;48:44–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8240476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Garcia E., Pelaez E., Roman J.C. Transverse myelitis following general and epidural anaesthesia in a paediatric patient. Anaesthesia. 2005;60:921–923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16115254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter R.W., Rosenberg R.N. Transverse myelitis associated with heroin addiction. JAMA. 1968;206(6):1255–1257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5695789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ell J.J., Uttley D., Silver J.R. Acute myelopathy in association with heroin addiction. J Neurol Neurosurg Psychiatry. 1981;44:448–450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC490993</ArticleId>
            <ArticleId IdType="pubmed">7264695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCreary M., Emerman C., Hanna J. Acute myelopathy following intranasal insufflation of heroin: a case report. Neurology. 2000;55:316–317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10908919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sahni V., Garg D., Garg S. Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. Clin Toxicol (Phila) 2008;46(2):153–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17917867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herregods P., Chappel R., Mortier G. Benzene poisoning as a possible cause of transverse myelitis. Paraplegia. 1984;22:305–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6493798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauer G.C. Transverse myelitis and paralysis from a brown recluse spider bite. Mo Med. 1975;72(10):603–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1181509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Misra U.K., Kalita K. Comparison of clinical and electrodiagnostic features in B12 deficiency neurological syndromes with and without antiparietal cell antibodies. Postgrad Med J. 2007;83(976):124–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2805935</ArticleId>
            <ArticleId IdType="pubmed">17308217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindenbaum J., Healton E.B., Savage D.G. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720–1728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3374544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naidich M.J., Ho S.U. Case 87: subacute combined degeneration. Radiology. 2005;237:101–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16183926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paliwal V.K., Malhotra H.S., Chaurasia R.N. “Anchor”-shaped bright posterior column in a patient with vitamin B12 deficiency myelopathy. Postgrad Med J. 2009;85:186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19417166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vorgerd M., Tegenthoff M., Kuhne D. Spinal MRI in progressive myeloneuropathy associated with vitamin E deficiency. Neuroradiology. 1996;38:S111–S113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8811695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutmann L., Shockor W., Gutmann L. Vitamin E-deficient spinocerebellar syndrome due to intestinal lymphangiectasia. Neurology. 1986;36(4):554–556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3960333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson J.S., Fitch C.D., Fischer V.W. Progressive neuropathologic lesions in vitamin E deficient rhesus monkeys. J Neuropathol Exp Neurol. 1981;40:166–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7463101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pineles S.L., Wilson C.A., Balcer L.J. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol. 2010;55(4):386–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20451943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naismith R.T., Shepherd J.B., Weihl C.C. Acute and bilateral blindness due to optic neuropathy associated with copper deficiency. Arch Neurol. 2009;66(8):1025–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893403</ArticleId>
            <ArticleId IdType="pubmed">19667226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nations S.P., Boyer P.J., love L.A. Denture cream: an unusual source of excess zinc leading to hypocupremia and neurologic disease. Neurology. 2008;71(9):639–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18525032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar N. Copper deficiency myelopathy (human swayback) Mayo Clin Proc. 2006;81(10):1371–1384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17036563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiser S.R., Winston G.P. Copper deficiency myelopathy. J Neurol. 2010;257:869–881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3691478</ArticleId>
            <ArticleId IdType="pubmed">20232210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatum W.O., Bui D.D., Grant E.G. Pseudo-Guillain-Barre syndrome due to "whippet"-induced myeloneuropathy. J Neuroimaging. 2010;20(4):400–401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19490402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renard D., Dutray A., Remy A. Subacute combined degeneration of the spinal cord caused by nitrous oxide anaesthesia. Neurol Sci. 2009;30(1):75–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19169627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng J., O'Grady G., Pettit T. Nitrous oxide use in first-year students at Auckland University. Lancet. 2009;361:1349–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12711474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spencer P.S., Ludoph A.C., Kisby G.E. Neurologic diseases associated with use of plant components with toxic potential. Environ Res. 1993;62:106–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8325256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerstner E.R., Batchelor T.T. Primary central nervous system lymphoma. Arch Neurol. 2010;67(3):291–297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20212226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrlinger U., Weller M., Kuker W. Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability. Neuroradiology. 2002;44(3):239–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11942380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flanagan E.P., O'Neill B.P., Porter A.B. Primary intramedullary spinal cord lymphoma. Neurology. 2011;77(8):784–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21832220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beristain X., Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol. 2002;59:439–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11890850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grove C.S., Robbins P.D., Kermode A.G. Intravascular lymphoma presenting as progressive paraparesis. J Clin Neurosci. 2008;15:1056–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18614371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang T., Tian L., Li Q. A case of intravascular B-cell lymphoma presenting as myelopathy and diagnosed postmortem. J Neurol Sci. 2008;272:196–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18620707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar N., Keegan A.M., Rodriguez F.J. Intravascular lymphoma presenting as a longitudinally-extensive myelitis: diagnostic challenges and etiologic clues. J Neurol Sci. 2011;303:146–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21247588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Podnar S. Epidemiology of cauda equina and conus medullaris lesions. Muscle Nerve. 2007;35:529–531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17143890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarz S., Zoubaa S., Knauth M. Intravascular lymphomatosis presenting with a conus medullaris syndrome mimicking disseminated encephalomyelitis. Neuro Oncol. 2002;4(3):187–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1920637</ArticleId>
            <ArticleId IdType="pubmed">12084349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng M., Knisely J. Post-radiotherapy myelitis observed in an AIDS patient with a meningioma: case report and review of the literature. J Neurooncol. 1999;45(2):167–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10778732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampling R., Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998;11(6):627–632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9870128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleyer A., Choi M., Wang S.J. Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;53:1205–1210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19821538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfonso E.R., De Gregorio M.A., Mateo P. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol. 1997;7(3):400–404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9087365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behrman A.L., Harkema S.J. Physical rehabilitation as an agent for recovery after spinal cord injury. Phys Med Rehabil Clin N Am. 2007;18(2):183–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17543768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atrice M.B. Lower extremity orthotic management for the spinal-cord-injured client. Spinal Cord Inj Rehabil. 2000;5(4):1–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Bailey S.N., Hardin E.C., Kobetic R. Neurotherapeutic and neuroprosthetic effects of implanted functional electrical stimulation for ambulation after incomplete spinal cord injury. J Rehabil Res Dev. 2010;47(1):7–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20437323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Everaert D.G., Thompson A.K., Chong S.L. Does functional electrical stimulation for foot drop strengthen corticospinal connections? Neurorehabil Neural Repair. 2010;24:168–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19861590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swinnen E., Duerinck S., Baeyens J.P. Effectiveness of robot-assisted gait training in persons with spinal cord injury: a systematic review. J Rehabil Med. 2010;42:520–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20549155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung R., Belanger A., Kanchiku T. Neuromuscular stimulation therapy after incomplete spinal cord injury promotes recovery of interlimb coordination during locomotion. J Neural Eng. 2009;6(5):055010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5036974</ArticleId>
            <ArticleId IdType="pubmed">19721184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman A.D., Brown T.R., Edwards K.R. A phase 3 trial of extended release oral dalframpridine in multiple sclerosis. Ann Neurol. 2010;68(4):494–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20976768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalsi V., Gonzales G., Popat R. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17890635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morton S.C., Shekelle P.G., Adams J.L. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil. 2002;83:129–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hess M.J., Hess P.E., Sullivan M.R. Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord. 2008;46:622–626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18392039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosma R., Wynia K., Havlikova E. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(1):1–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15932348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan F., Pallant J.F., Pallant J.I. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1033–1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20542931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasgupta P., Haslam C., Goodwin R. The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol. 1997;80(2):234–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9284194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasad R.S., Smith S.J., Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(1):42–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12617378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwendimann R.N. Treatment of symptoms in multiple sclerosis. Neurol Res. 2006;28:306–315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16687058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bywater A., While A. Management of bowel dysfunction in people with multiple sclerosis. Br J Community Nurs. 2006;11(8):333–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17044245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiesel P.H., Norton C., Roy A.J. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69(2):240–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1737071</ArticleId>
            <ArticleId IdType="pubmed">10896701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G., Macchiarella A., Cecconi F. Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. J Sex Med. 2009;6(12):3449–3457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19686427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G., Nelli F., Celso M. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. J Sex Med. 2012;9(4):970–985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22304626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimitriadis T., Karakitsios K., Tsounapi P. Erectile function and male reproduction in men with spinal cord injury: a review. Andrologia. 2010;42(3):139–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20500744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sipski M.L., Alexander C.J., Gomez-Marin O. Effects of vibratory stimulation on sexual response in women with spinal cord injury. J Rehabil Res Dev. 2005;42(5):609–616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16586186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Billups K.L., Berman L., Berman J. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther. 2001;27:435–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11554204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahrmann H., Cortelli P., Hilz M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930–936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16930356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faghri P.D., Yount J. Electrically induced and voluntary activation of physiologic muscle pump: a comparison between spinal cord-injured and able-bodied individuals. Clin Rehabil. 2002;16(8):878–885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12501950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raymond J., Davis G.M., Bryant G. Cardiovascular responses to an orthostatic challenge and electrical-stimulation-induced leg muscle contractions in individuals with paraplegia. Eur J Appl Physiol Occup Physiol. 1999;80(3):205–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10453922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Low P.A., Gilden J.L., Freeman R. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA. 1997;277(13):1046–1051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9091692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer W., Sandroni P., Opfer-Gehrking T.L. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16476804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathias C.J., Senard J.M., Braune S. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11710796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rabchevsky A.G., Patel S.P., Duale H. Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. Spinal Cord. 2011;49(1):99–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953609</ArticleId>
            <ArticleId IdType="pubmed">20514053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankel H.L., Mathias C.J. Severe hypertension in patients with high spinal cord lesions undergoing electro-ejaculation—management with prostaglandin E2. Paraplegia. 1980;18(5):293–299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7443281</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
